Search results
Results from the WOW.Com Content Network
A gastric emptying study is a nuclear medicine study which provides an assessment of the stomach's ability to empty. It may be used if there are complications after gastric surgery, for gastric reflux , or suspected gastroparesis amongst other indications. [ 1 ]
Gastroparesis (gastro- from Ancient Greek γαστήρ – gaster, "stomach"; and -paresis, πάρεσις – "partial paralysis") is a medical disorder of ineffective neuromuscular contractions (peristalsis) of the stomach, resulting in food and liquid remaining in the stomach for a prolonged period of time.
Rifampicin is the INN and BAN, while rifampin is the USAN. Rifampicin may be abbreviated R, RMP, RA, RF, or RIF (US). [citation needed] Rifampicin is also known as rifaldazine, [63] [64] rofact, and rifampin in the United States, also as rifamycin SV. [65]
A gastric emptying scintigraphy test involves eating a bland meal that contains a small amount of radioactive material. An external camera scans the abdomen to locate the radioactive material. The radiologist measures the rate of gastric emptying at 1, 2, 3, and 4 hours after the meal. The test can help confirm a diagnosis of dumping syndrome.
A gastric emptying study is considered the gold standard to assess the gastric emptying rate. [ 47 ] A large number of studies have indicated that most cases of peptic ulcers , and gastritis , in humans are caused by Helicobacter pylori infection, and an association has been seen with the development of stomach cancer .
Rifampin rapidly kills fast-dividing bacilli strains as well as "persisters" cells, which remain biologically inactive for long periods of time that allow them to evade antibiotic activity. [7] In addition, rifabutin and rifapentine have both been used against tuberculosis acquired in HIV-positive patients.
The first medication in this class, sitagliptin, received FDA approval in 2006 for the treatment of type 2 diabetes mellitus. The GLP-1 analogs principally act as agonists of the GLP-1 receptor and are thus insulinotropic. Exenatide was the first drug in this class to be used in the treatment of type 2 diabetes; it first received FDA approval ...
The condition frequently causes digestive symptoms, epigastric pain, constipation, decreased appetite, and sometimes even gastric emptying disorders. [2] It is much more prominent in women than men, and is diagnosed with x-ray using barium contrast .